Download - Monobactams Antibiotics
MonobactamsLucas Cruz, Brasil
Chromobacterium violaceum
Enzymatic
inactivation
Antibiotic efflux
Modification of the
target receptor
Difficulty of
penetrating the
cell
Resistance
Spectrum of Action:
Aerobic Gram-negatives
IV ou IM
Pharmacokinetics
Drug Interactions
Clinical use
Urinary Tract Infection
Gram-negative sepsis
Cystic
Fibrosis
1 g, 8/8 or 12/12H
Via IV
500mg, 12H
2g, de 6/6h
30mg/kg 12, 8 our6/6h
Dose
Side effects
Comercial presentation
1. Aztreonam acts only against gram-negative aerobiic
2.Is resistant to beta-lactamases
3. Few side effects
4. It is useful in the treatment of patients allergic to penicillin
Don’t
forget:
Bibliografic References:
• TAVARES, W. Antibióticos e quimioterápicos para o clínico/Walter Tavares. 2ª ed. Ver. e atual. São Paulo: Editora Atheneu, 2009. p. 210 a 212.
• VINKS, A. A.. et al. Pharmacokinetics of Aztreonam in Healthy Subjects and Patients with Cystic Fibrosis and Evaluation of Dose-Exposure Relationships Using Monte Carlo Simulation. 2007. American Society for microbiology. Disponível em:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2043218/?tool=pubmed/ Acessado em: 04 de dezembro de 2010.
• WALKININE, Y. FDA Approves Inhaled Aztreonam for Cystic Fibrosis. 2010. MedScape. Disponível em: http://www.medscape.com/viewarticle/717553 Acessado em: 05 de dezembro de 2010.